[go: up one dir, main page]

SI1689404T1 - Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka - Google Patents

Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka

Info

Publication number
SI1689404T1
SI1689404T1 SI200430928T SI200430928T SI1689404T1 SI 1689404 T1 SI1689404 T1 SI 1689404T1 SI 200430928 T SI200430928 T SI 200430928T SI 200430928 T SI200430928 T SI 200430928T SI 1689404 T1 SI1689404 T1 SI 1689404T1
Authority
SI
Slovenia
Prior art keywords
combination
cancer
drugs
treatment
fluorouracil
Prior art date
Application number
SI200430928T
Other languages
English (en)
Inventor
Mary Ellen Rybak
Original Assignee
Pharma Mar Sau
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sau filed Critical Pharma Mar Sau
Publication of SI1689404T1 publication Critical patent/SI1689404T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SI200430928T 2003-11-13 2004-11-15 Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka SI1689404T1 (sl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US51969003P 2003-11-13 2003-11-13
PCT/GB2004/050026 WO2005049031A1 (en) 2003-11-13 2004-11-15 Combination
EP04798717A EP1689404B9 (en) 2003-11-13 2004-11-15 Combination of et-743 with 5-fluorouracil pro-drugs for the treatment of cancer

Publications (1)

Publication Number Publication Date
SI1689404T1 true SI1689404T1 (sl) 2009-02-28

Family

ID=34619369

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200430928T SI1689404T1 (sl) 2003-11-13 2004-11-15 Kombinacija et-743 s 5-fluorouracil pro zdravili za zdravljenje raka

Country Status (15)

Country Link
US (1) US7622458B2 (sl)
EP (1) EP1689404B9 (sl)
JP (1) JP2007511499A (sl)
AT (1) ATE406897T1 (sl)
CA (1) CA2544320A1 (sl)
CY (1) CY1108629T1 (sl)
DE (1) DE602004016376D1 (sl)
DK (1) DK1689404T3 (sl)
ES (1) ES2314470T3 (sl)
HR (1) HRP20080598T3 (sl)
PL (1) PL1689404T3 (sl)
PT (1) PT1689404E (sl)
RS (1) RS50692B (sl)
SI (1) SI1689404T1 (sl)
WO (1) WO2005049031A1 (sl)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY164077A (en) 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
MXPA02011319A (es) 2000-05-15 2003-06-06 Pharma Mar Sa Analogos antitumorales de ecteinascidina 743.
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
GB0117402D0 (en) * 2001-07-17 2001-09-05 Pharma Mar Sa New antitumoral derivatives of et-743
GB0202544D0 (en) * 2002-02-04 2002-03-20 Pharma Mar Sa The synthesis of naturally occuring ecteinascidins and related compounds
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
US20080255132A1 (en) * 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
PL1827500T3 (pl) * 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
DK1658848T3 (da) 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid
AU2006272343B2 (en) * 2005-07-21 2012-09-13 Nuvo Research Ag Stabilized chlorite solutions in combination with fluoropyrimidines for cancer treatment.
GB0522082D0 (en) 2005-10-31 2005-12-07 Pharma Mar Sa Formulations
RU2325914C2 (ru) * 2006-06-15 2008-06-10 Государственное учреждение научно-исследовательский институт онкологии Томского Научного центра Сибирского отделения Российской академии медицинских наук (ГУ НИИ онкологии ТНЦ СО РАМН) Способ лечения операбельного рака молочной железы
AU2008313634A1 (en) * 2007-10-19 2009-04-23 Pharma Mar, S.A. Prognostic molecular markers for ET-743 treatment
SI2786753T1 (sl) 2010-11-12 2019-05-31 Pharma Mar S.A. Kombinacijska terapija s protitumorskim antibiotikom
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CA3090748A1 (en) * 2018-02-12 2019-08-15 Array Biopharma Inc. Methods and combination therapy to treat biliary tract cancer
PH12022551216A1 (en) 2019-11-21 2023-07-17 Pharma Mar Sa Methods of treating small cell lung cancer with lurbinectedin formulations

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5256663A (en) * 1986-06-09 1993-10-26 The Board Of Trustees Of The University Of Illinois Compositions comprising ecteinascidins and a method of treating herpes simplex virus infections therewith
US5149804A (en) * 1990-11-30 1992-09-22 The Board Of Trustees Of The University Of Illinois Ecteinascidins 736 and 722
US5089273A (en) * 1986-06-09 1992-02-18 Board Of Trustees Of The University Of Illinois Ecteinascidins 729, 743, 745, 759A, 759B and 770
DE3635711A1 (de) * 1986-10-21 1988-04-28 Knoll Ag 5-nitrobenzo(de)isochinolin-1,3-dione, ihre herstellung und verwendung
FR2697752B1 (fr) * 1992-11-10 1995-04-14 Rhone Poulenc Rorer Sa Compositions antitumorales contenant des dérivés du taxane.
AU671491B2 (en) * 1992-12-18 1996-08-29 F. Hoffmann-La Roche Ag N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines
US5478932A (en) * 1993-12-02 1995-12-26 The Board Of Trustees Of The University Of Illinois Ecteinascidins
US20040059112A1 (en) * 1994-02-18 2004-03-25 Rinehart Kenneth L. Ecteinascidins
GB9508195D0 (en) * 1995-04-20 1995-06-07 Univ British Columbia Novel biologically active compounds and compositions,their use and derivation
US5721362A (en) * 1996-09-18 1998-02-24 President And Fellows Of Harvard College Process for producing ecteinascidin compounds
US5985876A (en) * 1997-04-15 1999-11-16 Univ Illinois Nucleophile substituted ecteinascidins and N-oxide ecteinascidins
EP1876180A3 (en) * 1998-04-06 2009-12-16 The Board Of Trustees Of The University Of Illinois Semi-synthetic ecteinascidins
KR100643092B1 (ko) 1998-05-11 2006-11-10 파르마 마르, 에스.에이. 엑테인아시딘 743의 대사산물
MY164077A (en) * 1999-05-13 2017-11-30 Pharma Mar Sa Compositions and uses of et743 for treating cancer
AR035842A1 (es) 1999-05-14 2004-07-21 Pharma Mar Sa Metodo de hemisintesis para la formacion de compuestos intermediarios y derivados y de estructuras relacionadas con la ecteinascidina y de tetrahidroisoquinolinfenoles y compuestos intermediarios de aplicacion en dicho metodo
CZ298259B6 (cs) * 2000-02-28 2007-08-08 Aventis Pharma S. A. Farmaceutická kombinace k lécení rakoviny obsahující CPT-11 a capecitabin
MXPA02010088A (es) 2000-04-12 2004-08-19 Pharma Mar Sa Derivados de ecteinascidina antitumorales.
JP2004506430A (ja) * 2000-08-11 2004-03-04 シティ・オブ・ホープ Ｓｘｒによるトランス活性化の抗新生物剤ｅｔ−７４３による阻害
BR0115162A (pt) * 2000-11-06 2003-10-21 Pharma Mar Sa Tratamentos antitumorais eficazes
EP1360337A1 (en) 2001-02-09 2003-11-12 The Regents Of The University Of California Ecteinascidin family compounds: compositions and methods
GB0121285D0 (en) 2001-09-03 2001-10-24 Cancer Res Ventures Ltd Anti-cancer combinations
EP1435988A4 (en) 2001-10-19 2008-01-09 Pharmamar Sa IMPROVED USE OF ANTI-TUMORAL COMPOUND IN THE TREATMENT OF CANCER
US20040019027A1 (en) * 2002-04-12 2004-01-29 Barry Forman Method of treating cerebrotendinous xanthomatosis
GB0312407D0 (en) * 2003-05-29 2003-07-02 Pharma Mar Sau Treatment
GB0324201D0 (en) * 2003-10-15 2003-11-19 Pharma Mar Sau Improved antitumoral combinations
PT1689404E (pt) 2003-11-13 2008-12-15 Pharma Mar Sau Combinação de et-743 com pró-fármacos de fluorouracil para o tratamento do cancro
US20080255132A1 (en) 2003-11-14 2008-10-16 Eric Rowinsky Combination Therapy Comprising the Use of Et-743 and Paclitaxel for Treating Cancer
GB0326486D0 (en) * 2003-11-14 2003-12-17 Pharma Mar Sau Combination treatment
JP2008514688A (ja) 2004-09-29 2008-05-08 ファルマ・マル・エス・アー， ソシエダッド・ユニペルソナル 抗炎症剤としてのエクテイナシジン化合物
PL1827500T3 (pl) 2004-10-26 2009-09-30 Pharma Mar Sa Pegylowana liposomalna doksorubicyna w kombinacji z ekteinascydyną 743
DK1658848T3 (da) * 2004-10-29 2007-11-26 Pharma Mar Sa Formuleringer omfattende ecteinascidin og et disaccharid

Also Published As

Publication number Publication date
DK1689404T3 (da) 2009-01-26
DE602004016376D1 (de) 2008-10-16
US7622458B2 (en) 2009-11-24
EP1689404A1 (en) 2006-08-16
CY1108629T1 (el) 2014-04-09
RS50692B (sr) 2010-06-30
PL1689404T3 (pl) 2009-02-27
US20070190164A1 (en) 2007-08-16
WO2005049031A1 (en) 2005-06-02
JP2007511499A (ja) 2007-05-10
EP1689404B1 (en) 2008-09-03
EP1689404B9 (en) 2009-04-22
ES2314470T3 (es) 2009-03-16
CA2544320A1 (en) 2005-06-02
HRP20080598T3 (en) 2009-01-31
ATE406897T1 (de) 2008-09-15
PT1689404E (pt) 2008-12-15

Similar Documents

Publication Publication Date Title
CY1108629T1 (el) Συνδυασμος ετ 743 με 5 φθοριοουρακιλο προ-φαρμακα δια την θεραπευτικη αγωγη του καρκικου
IL273765A (en) Combinations and forms of administration of therapeutic agents and combined treatment
WO2004062604A3 (en) Treatment of cancer with 2-deoxyglucose
NZ544472A (en) Compounds and therapeutical use thereof
NZ514464A (en) Apomorphine and sildenafil composition
IL155781A0 (en) Effective antitumor treatments
SI1551409T1 (sl) Uporaba kinazolinskega derivata ZD6474, kombiniranega z gemcitabinom in po želji ionizirajočim obsevanjem, pri zdravljenju raka
WO2006113802A3 (en) Device for administering electrode stimulation of back and abdominal muscles
MY138059A (en) Use of ikb-kinase inhibitors in pain therapy
NO20072543L (no) Anti-cancer-behandling
MY164077A (en) Compositions and uses of et743 for treating cancer
WO2000057867A3 (en) Improved cancer treatment with temozolomide
DE60301862D1 (de) Kombinationsbehandlung bei akutem myokardinfarkt
AU2001236529A1 (en) Combination therapy for cancer
IL159770A0 (en) Calcium salts with cytotoxic activity
WO2006124573A3 (en) Treatment of cancer with 2-deoxyglucose
UA11290U (uk) Спосіб профілактики антрациклінового ушкодження серця